US drug approvals
2 approvals with a product on the US market
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
Free public records show Everest Life Sci in 1 of the markets we cover. It is not a key player in our research.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
2 approvals with a product on the US market
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
Markets we cover where free public records show Everest Life Sci: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Everest Life Sci is in.
Stories on the topics Everest Life Sci works in.
Collagen powders promise younger skin and easier joints. A 2025 review of 23 trials found the benefits…
Read
Skin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Read
TB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade…
Read